

ANNEX A - STANDARDISED DISCLOSURE TEMPLATE SWEDISH ORPHAN BIOVITRUM 2024

Date of publication: 30/06/2025

	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country local identifier OPTIONAL	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.d)			TOTAL OPTIONAL
	(Art. 1.01)	(Art. 3)	(Schedule 1)	(Art. 3)	(Art. 3)		Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accomodation	Fees	Related expenses agreed in the fee for service or consultancy contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
						N/A	N/A	0	0	0	0		0
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2					N/A	N/A	0	0	0	0		0
	Number of Recipients (named list, where appropriate) - Art. 3.2					N/A	N/A	0	0	0	0		0
HCOs	% of total transfers of value to individual HCPs - Art. 3.2					N/A	N/A	0%	0%	0%	0%		0%
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
						0	0	0	0	0	0		0
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2					0	0	0	0	0	0		0
R&D	Number of Recipients (named list, where appropriate) - Art. 3.2					0	0	0	0	0	0		0
	% of total transfers of value to individual HCOs - Art. 3.2					0%	0%	0%	0%	0%	0%		0%
	AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											136827.88	136827.88